MIRM

Mirum Pharmaceuticals

• NASDAQ·3d ago

  FDA Drug Approvals In September 2026

• Dow Jones·4d ago

  Mirum Pharmaceuticals Price Target Raised to $156.00/Share From $136.00 by Stifel

• Dow Jones·4d ago

  Mirum Pharmaceuticals Is Maintained at Buy by Stifel

• Benzinga·5d ago

  Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156

• TipRanks·5d ago

  Analyst Lifts Mirum Price Target to $156 on De-Risked Pipeline and Strengthened Commercial Outlook

• TipRanks·5d ago

  Mirum Pharmaceuticals price target raised to $156 from $136 at Stifel

• Dow Jones·6d ago

  Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

• Dow Jones·6d ago

  Mirum Pharmaceuticals Price Target Raised to $146.00/Share From $135.00 by Evercore ISI Group

• Benzinga·6d ago

  Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146

• TipRanks·10/13 13:05

  JPMorgan’s Fye Reaffirms Buy on Mirum as Strong Livmarli Phase III Data De-Risk sNDA Path and Support Billion-Dollar Peak Sales Outlook

• TipRanks·10/13 12:37

  Mirum Pharmaceuticals price target raised to $146 from $135 at Evercore ISI

• TipRanks·10/13 12:28

  Mirum Pharmaceuticals Reports Positive Phase 3 LIVMARLI Results

• Dow Jones·10/13 10:15

  Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

• Dow Jones·10/13 10:15

  Mirum Pharmaceuticals Price Target Raised to $152.00/Share From $137.00 by Morgan Stanley

• Benzinga·10/13 10:04

  Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152